Kate Markey, MBBS, PhD, FRACP , an assistant professor at Fred Hutch Cancer Center and UW Medicine, has recently been named ...

Watch out, metastatic ER+/HER2- breast cancer. There’s a new targeted agent in town. On Tuesday, the U.S. Food and Drug Administration approved the drug gedatolisib, a multi-targeted kinase inhibitor ...

Eight Fred Hutch researchers receive nearly $1 million to advance projects with industry partnership potential ...

The Damon Runyon Cancer Research Foundation recently awarded two Fred Hutch postdoctoral fellows grants to support ...

Student Program hosts local high school students in grades 11 and 12 for an inside look at the many career opportunities at a ...

Moderation matters: Red meat isn’t inherently “bad,” but Americans eat far more than recommended. Higher consumption leads to more risk: Red meat is linked to colorectal cancer, cardiovascular disease ...

After experiencing facial paralysis, 75-year-old Bob Duncan of Corvallis, Oregon, was diagnosed with a rare form of squamous cell carcinoma that spreads along nerves and cannot be surgically removed.

Since its earliest days, Fred Hutch Cancer Center's story has been closely tied to bone marrow transplantation. E. Donnall Thomas, MD, Fred Hutch’s first director of medical oncology, pioneered this ...

I am a certified physician assistant who sees patients at the Sloan Clinic and Fred Hutch at UW Medical Center - Montlake. I see patients in the ACE clinic, or Acute Clinical Evaluation clinic. We are ...

Fred Hutch’s Drs. Petros Grivas and Sara Hurvitz discuss clinical trials, multidisciplinary care, community outreach and the importance of varied perspectives in leadership.

For Dina Lorraine, going on the GLP-1 drug Zepbound in April of 2025 was a no-brainer. “I had no energy,” said the 58-year-old public relations professional from Auburn, Washington, who’s been treated ...

Rare cancer expert Taran Gujral, PhD, cares more about what a cancer drug can do than what it is designed to do. His lab at Fred Hutch Cancer Center investigates a promising target for cancer drugs — ...